This reference antibody targets the CD200R1 (OX2R) receptor on immune cells, particularly myeloid cells, by blocking CD200-CD200R1 inhibitory signaling, thereby enhancing immune activation. It is primarily explored in oncology and infectious diseases to boost anti-tumor or anti-pathogen immunity, such as in combination with checkpoint inhibitors to modulate the tumor microenvironment. Applications focus on research and clinical development for immune checkpoint agonism/antagonism, with potential in Janssen-patented therapies.